- Palivizumab, sold
under the
brand name
Synagis, is a
monoclonal antibody produced by
recombinant DNA
technology used to
prevent severe disease caused...
- in Gaithersburg, MD, Cambridge, UK, and
Mountain View, CA. It
produced Synagis, a drug for the
prevention of
respiratory infections in infants, which...
- haemophilia;
Doptelet for ITP and CLD;
Kineret for
several disorders;
Synagis for RSV and
Gamifant for pHLH, and the 2020
annual report shows a further...
-
antibody (MAb) that can be
delivered through muscular injection.
Palivizumab (
Synagis) is a
monoclonal antibody directed against the
surface fusion (F) protein...
- Hib, and a
preventive therapy for
respiratory syncytial virus or RSV (
Synagis). Additionally,
NIAID partnerships with
industry and
academia have led...
-
included trastuzumab (Herceptin),
bevacizumab (Avastin), and
palivizumab (
Synagis). It held its
initial public offering in 1992 and by 1994 it had 13 compounds...
- that
nirsevimab had a
similar safety profile compared to
palivizumab (
Synagis). The US Food and Drug
Administration (FDA)
evaluated the
safety and efficacy...
- 301,414 9.59% Novo
Nordisk Diabetes mellitus type 2 May-1909 Mon-20XX 47
Synagis Palivizumab 289,704 0.00%
MedImmune RSV
infection Feb-1998 Aug-2012 48...
- two
years the
product demand began to
exceed the
supply of
plasma and
Synagis, the
first humanized monoclonal antibody was
approved in its place. Monoclonal...
- 1056/NEJMoa1604330. PMC 5086427. PMID 27732819. "Label -
Palivizumab (
Synagis), Medimmune, Incorporated" (PDF).
Retrieved 4
February 2020. VanBlargan...
